OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from โ1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
PULM
Pulmatrix, Inc.
There isn't enough reported data to score PULM yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PULM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
PULM's revenue is currently stable, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | โ |
| Current | 13x | $31.94 | โ |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
PULM PE Valuation
PULM has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
PULM Forward outlook
There aren't enough analyst estimates for PULM to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over PULM on earnings quality, reporting a profit while its opponent remains loss making.
PULM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.10 | +$1.08 |
| Q1 2026 | -$1.23 | +$2.12 |
| Q4 2025 | -$1.41 | +$1.21 |
| Q3 2025 | -$1.71 | +$0.94 |
| Q2 2025 | -$2.18 | +$0.79 |
| Q1 2025 | -$3.35 | -$0.93 |
| Q4 2024 | -$2.62 | +$1.25 |
| Q3 2024 | -$2.65 | +$1.86 |
PULM is still losing money, but far less than before: $1.10 per share over the past year, against $30.58 at its worst in late 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the stronger quarterly revenue trend. Revenue is up 72% for OSCR versus down 100% for PULM.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
PULM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $3K | -100% |
| Q3 2024 | $366K | -79% |
| Q2 2024 | $1.6M | -16% |
| Q1 2024 | $5.9M | +293% |
| Q4 2023 | $2.2M | +29% |
| Q3 2023 | $1.8M | -6.4% |
| Q2 2023 | $1.8M | +39% |
| Q1 2023 | $1.5M | +29% |
PULM's revenue is growing: $3,000 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -65067% | -64966 points |
| Q3 2024 | -726% | -501 points |
| Q2 2024 | -380% | -164 points |
| Q1 2024 | 13% | +319 points |
| Q4 2023 | -101% | +152 points |
| Q3 2023 | -225% | +48 points |
| Q2 2023 | -216% | +126 points |
| Q1 2023 | -306% | +122 points |
PULM's operating margin was โ65067% last quarter, down 64966 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with PULM at up 57%.
PULM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$1.3M | +$1.1M |
| Q3 2024 | -$3.1M | +$1.4M |
| Q4 2023 | -$2.3M | +$2.7M |
| Q3 2023 | -$4.5M | -$851K |
| Q4 2022 | -$5.1M | -$633K |
| Q3 2022 | -$3.6M | -$192K |
| Q4 2021 | -$4.4M | -$1.6M |
| Q3 2021 | -$3.4M | +$2.2M |
PULM has burned cash in almost every quarter: โ$6M over the past year, against โ$14M the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
PULM Net Leverage
PULM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PULM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.6 | Neutral |
| Stochastic | 32.3 | Neutral |
PULM's weekly RSI is 38 (neutral) and its Stochastic is 32 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PULM PE vs Healthcare Sector
PULM has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over PULM on trend strength, trading above more of its moving averages.
PULM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.44 | 9.7% below |
| 20 week MA | $1.53 | 15% below |
| 50 week MA | $1.85 | 30% below |
| 100 week MA | $4.03 | 68% below |
| 200 week MA | $3.27 | 60% below |
PULM is in a downtrend: it's below all five of its weekly moving averages, and 60% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PULM on returns for 2026, with the stronger performance.
PULM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.8 | $24.6 | +46% |
| 2021 | $24.6 | $8.60 | -65% |
| 2022 | $8.60 | $3.50 | -59% |
| 2023 | $3.50 | $1.86 | -47% |
| 2024 | $1.86 | $6.40 | +244% |
| 2025 | $6.40 | $2.34 | -63% |
| 2026 YTD | $2.34 | $1.30 | -44% |
PULM's yearly returns have swung widely, from +244% in 2024 to โ65% in 2021. It's down 44% so far in 2026.